Category Archives: New York Stem Cells

Suzanne Corkins 2013 book Permanent Present Tense falls into this category. Corkin, a research psychologist, presents a fascinating case study of her patient, Henry Molaison, a man with no memory. Molaison or H.M., as he was known in the scientific literature until his death in 2008 was a 27-year-old with severe epilepsy when he underwent radical brain surgery in 1953 to cure his intractable seizures. His Yale surgeon, William Scoville, drilled two holes in the skull just above his eyes and suctioned out a small cupful of tissue from both his medial temporal lobes. The excised tissue included the olfactory lobes, which regulate smell, the amygdala, which controls emotions, and half of the hippocampus, whose function was not properly understood at the time.

Though Molaisons seizures largely abated after the operation, he developed an even bigger problem, which manifested almost immediately after his surgery. He couldnt remember who his hospital caregivers were, no matter how many times he was introduced to them. He got lost going to the bathroom, no matter how many times he was shown where it was. Daily events vanished from his mind almost as soon as they had occurred. The condition was called anterograde amnesia.

His amnesia was eventually traced to damage to the hippocampus, a structure critically concerned in the retention of current experience, as Scoville and a colleague later wrote. His existing memories remained largely intact. He could still remember vacations with his parents, jobs hed held as a teenager, going target shooting with his father and other events from his childhood. Yet, like most patients living with dementia, he could form no new long-term memories. With no new memories, he lived in a perpetual present, disconnected from his past (or at least the past after his surgery) and his future. It was like waking from a dream, he told Corkin. Every day is alone in

itself.

Though dementia today is better understood than ever before, the therapeutic landscape for the condition has only recently gotten a bit less bleak. In early June, the F.D.A. approved the first new medication for Alzheimers disease in nearly two decades. And though the approval process has been subject to controversy and its not clear how well the drug actually works, the decision represents some movement after hundreds of experimental remedies have failed in hundreds of clinical trials. Yet its still accurate to say that dementia remains the only chronic and widespread medical scourge for which there are literally no effective treatments.

A recent book that explores this Sisyphean search for a cure is In Pursuit of Memory: The Fight Against Alzheimers, by Joseph Jebelli, published in 2017. A British neuroscientist, Jebelli travels around the world to discover the latest in dementia research. He goes to Papua New Guinea, Japan, India and China to learn about experimental (but mostly futile) treatments, including stem cells, blood transfusions and repurposed cancer drugs. In the end, he acknowledges how little medicine currently has to offer patients living with dementia, even as he holds out hope (far-fetched, in my view) for a cure in 10 years.

Read the original here:
Turning to Books to Grasp the Most Ungraspable Disease - The New York Times

by registering a CAGR of 15. 25% until 2026. Cell isolation is a technique of isolating cells for diagnosis and analysis of a particular type of cell. The market growth can be attributed to the rising demand for drugs, vaccines and other related products, as they are manufactured with the assistance of cell isolation technique.

New York, June 03, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cell Isolation Market - Competition Forecast & Opportunities, 2026" - https://www.reportlinker.com/p06089447/?utm_source=GNW Increasing popularity of precision medicines is also working in the favor of the market growth.

Global cell isolation market has been segmented into product, cell type, source, technique, application, end-user, company and region.Based on technique, the market is further fragmented into centrifugation-based cell isolation, surface-marker based cell isolation and filtration-based cell isolation, amongst which, centrifugation-based cell isolation segment occupied the largest market share in 2020 as it finds extensive applications in various end user sectors such as academic institutes, research laboratories, etc.

Based on application, the market is further divided into biomolecule isolation, cancer research, stem cell research, in vitro diagnostics and others.Among these, cancer research and stem cell research are projected to be the lucrative segments of the market in the forecast period.

Increase in the research activities by biopharma companies and laboratory is the key factor for the growth of the segments.

Based on regional analysis, Asia-Pacific is expected to grow at the highest CAGR during the forecast period.The high CAGR of the region can be attributed to the relaxation in the stringent rules and regulations laid down by the government for drug development.

Another factor that can be held responsible for the fastest growth of the region is the availability of competent researchers and personnel who can carry out cell isolation techniques along with a wide genome pool.

Major players operating in the global cell isolation market include GE Healthcare Inc., Stemcell Technologies Inc., Danaher Corporation (Beckman Coulter Inc.), Becton, Dickinson and Company, Merck KGaA, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Terumo Corporation, Sartorius AG, Cell Biolabs Inc., Miltenyi Biotec GmbH, F. Hoffmann-La Roche AG, Corning Inc, Akadeum Life Sciences, Inc., Invent Biotechnologies, Inc. and others. The market players are focusing on research and development activities in order to enhance their product portfolios and strengthen their position across the global market. For instance, the major pharmaceutical companies worldwide are making substantial investments in R&D to introduce new drugs in the market. Such investments are expected to increase the demand for cell isolation products over the coming years. In addition to this, new product developments help vendors to expand their product portfolio and gain maximum share in the sector. For example, Thermo Scientifics Medifuge is a benchtop centrifuge which is having a unique hybrid rotor as well as an interchangeable swing-out buckets and fixed-angle rotors to facilitate rapid & convenient applications on a single platform. Moreover, collaborations, mergers & acquisitions and regional expansions are some of the other strategic initiatives taken by major companies for serving the unmet needs of their customers.

Years considered for this report:

Historical Years: 2016-2019Base Year: 2020Estimated Year: 2021Forecast Period: 2022-2026

Objective of the Study:

To analyze the historical growth in the market size of global cell isolation market from 2016 to 2020. To estimate and forecast the market size of global cell isolation market from 2021 to 2026 and growth rate until 2026. To classify and forecast global cell isolation market based on product, cell type, source, technique, application, end-user, company and region. To identify dominant region or segment in the global cell isolation market. To identify drivers and challenges for global cell isolation market. To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global cell isolation market. To conduct pricing analysis for global cell isolation market. To identify and analyze the profile of leading players operating in global cell isolation market. To identify key sustainable strategies adopted by market players in global cell isolation market.The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of companies and laboratories using cell isolation techniques across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the companies and laboratories using cell isolation techniques which could not be identified due to the limitations of secondary research. The analyst examined the companies and laboratories using cell isolation techniques and presence of all major players across the globe.The analyst calculated the market size of global cell isolation market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

Companies and laboratories using cell isolation techniques, research labs, end users and other stakeholders Government bodies such as regulating authorities and policy makers Organizations, forums and alliances related to cell isolation Market research and consulting firmsThe study is useful in providing answers to several critical questions that are important for the industry stakeholders such as research labs, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global cell isolation market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: Global Cell Isolation Market, By Product:o Consumableso Instruments Global Cell Isolation Market, By Cell Type:o Human Cellso Animal Cells Global Cell Isolation Market, By Source:o Bone Marrowo Cord Blood/Embryonic Stem Cellso Adipose Tissue Global Cell Isolation Market, By Technique:o Centrifugation-Based Cell Isolationo Surface Marker-Based Cell Isolationo Filtration-Based Cell Isolation Global Cell Isolation Market, By Application:o Biomolecule Isolationo Cancer Researcho Stem Cell Researcho In Vitro Diagnosticso Others Global Cell Isolation Market, By End-User:o Biotechnology and Biopharmaceutical Companieso Research Laboratories and Instituteso Hospitals and Diagnostic Laboratorieso Cell Banks Global Cell Isolation Market, By Region:o North AmericaUnited StatesMexicoCanadao EuropeGermanyUnited KingdomFranceItalySpaino Asia-PacificChinaJapanIndiaSouth KoreaAustraliao South AmericaBrazilArgentinaColombiao Middle East and AfricaSouth AfricaSaudi ArabiaUAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global cell isolation market.

Available Customizations:

With the given market data, we offers customizations according to a companys specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).Read the full report: https://www.reportlinker.com/p06089447/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

The rest is here:
Global cell isolation market was valued at USD7013.71 million in 2020 and is anticipated to reach USD15529.45 million by 2026 - Yahoo Finance

Transcript

Hi, my name is Adriana Rossi. I am an associate director of the Myeloma Program at Weill Cornell Medicine in New York.

Autologous stem cell transplant has been a standard of care for myeloma for decades. So far, the only approved regimen we have is highdose melphalan. Over the years, we have tried different combinations with radiation or with drugs such as busulfan and bortezomib, but so far, nothing has proved superior than the single agent.

The introduction of lenalidomide has changed the landscape of myeloma and therapy for our patients. When we first started studying it, we saw that there's a clear doseresponse curve, but we are limited by myelosuppression. Our thought was in the setting of stem cell reconstitution, could we push the dose of lenalidomide to get a maximal benefit and overcome that toxicity with the use of stem cells?

We studied 50 patients with relapsed myeloma. Many of whom had prior transplants, and many of whom came into the study with progressive disease. We used a regimen of the 200 of melphalan, which is standard, and additionally added 350 mg daily for 5 days of lenalidomide.

At day 100, the overall response rate was 96%, being that over 80% were VGPR or greater. A remarkable depth of response for patients who are very highrisk. The response was regardless of prior transplantation, regardless of prior lenalidomide, and regardless of high-risk cytogenetics.

We are very encouraged by the findings so far and if we can improve our current practice for transplant and using 2 drugs get deeper responses and be able to salvage patients with limited options, this could be practicechanging.

I think this was a very valuable proof of concept and really merits further investigation either moving forward with a greater patient cohort and having a comparative arm, so a randomized control study, or also we are considering other agents that we could use, be that pomalidomide or the CELMoDs that are coming into practice.

Read the original post:
Dr Rossi Talks Lenalidomide, Melphalan as Effective Conditioning Regimen for ASCT in R/R MM - Oncology Learning Network

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from their collaboration with the University of Cologne (Kln, Germany) demonstrating that decreased microbiome diversity in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is associated with poor clinical outcomes including mortality and increased incidence of intestinal graft-versus-host disease (GvHD). The data are being presented in an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually. A separate poster presentation, including data from a collaboration with Memorial Sloan Kettering Cancer Center (New York, NY), established a significant association between microbiome composition and response to immune checkpoint inhibitor (ICI) treatment in patients who have metastatic melanoma, metastatic lung (NSCLC), urothelial, or renal cancer.

Seres is advancing development programs in oncology to evaluate the potential of microbiome therapeutics to modulate host immunity or inflammation to improve response and tolerability of cancer treatments. This includes SER-155, an investigational, oral, rationally-designed, cultivated microbiome therapeutic, which is advancing into a Phase 1b clinical trial to reduce the incidence of antibiotic-resistant bacterial infections and GvHD in patients following transplant procedures.

Disruption of microbiome-modulated functions can impact clinical outcomes for patients being treated for cancer, including those who are undergoing allogeneic hematopoietic stem cell transplantation and those treated with cancer immunotherapy, said Lisa von Moltke, M.D., Chief Medical Officer at Seres. The findings we are presenting at ASCO provide further evidence that our SER-155 program, as well as our earlier stage oncology programs, will help to advance our understanding of the potential of microbiome therapeutics to work with the bodys immune system to improve cancer treatment outcomes.

Clinical Evidence of Impact of Microbial Diversity on Mortality and GvHD in HSCT Patients

In collaboration with the University of Cologne, a prospective observational study was conducted to evaluate changes in microbial diversity over time in acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) patients undergoing allogeneic HSCT and the impact on clinical outcomes. Patients were administered antibiotics as empiric treatment for febrile neutropenia or as targeted treatment and were monitored for incidence of GvHD. Stool was collected on a weekly basis prior to an HSCT procedure and up to 28 days post HSCT, with additional samples collected at days 56, 90, and 365, as well as upon diagnosis of intestinal GvHD. Gut microbiome profiles were generated from 381 stool samples (representing 65 subjects) to evaluate the relationship between gastrointestinal microbial diversity over time and clinical outcome.

Frequent complications associated with stem cell transplantation include antibiotic-resistant infection and GvHD. Current treatments for the prevention of GvHD rely on increased immunosuppression, leaving the patient susceptible to a host of bacterial infections and offer limited efficacy. The findings from this prospective study demonstrate a need for continued investigation into the use of microbiome therapeutics to reduce morbidity and mortality among transplant recipients, said Christopher Ford, Ph.D., Senior Director, Computational Microbiome Sciences at Seres Therapeutics and co-author of the presentation.

Twenty-eight patients (42%) developed intestinal GvHD and 16 (25%) died prior to study completion. Across all subjects, a decline in microbiome diversity was observed immediately following HSCT. Decreased diversity and intestinal domination by two bacterial groups Enterococcus and Enterobacteriaceae - was significantly associated with mortality across the study time course (p

Evaluation of Microbiome Composition in Correlation to Cancer-Specific Immune Checkpoint Inhibitor (ICI) Response

A study conducted with Memorial Sloan Kettering explored the relationship between microbiome composition and ICI response in patients with metastatic melanoma, metastatic lung (NSCLC), urothelial, or renal cancer. Fecal microbiome samples were collected from 94 patients (metastatic melanoma, n=17, NSCLC, n=44, urothelial, n=23, renal cancer, n=10) immediately before ICI therapy. Bacterial genomic DNA was isolated and profiled by whole metagenomic sequencing to evaluate bacterial signatures associated with response (R) and nonresponse (NR).

Treatment included anti-PD(L)1 monotherapy (n=51), anti-PD1 + anti-CTLA4 combination therapy (n=17), or a combination of anti-PD1 and chemotherapy (n=26). Clinical response was observed in 58% of patients, including partial or complete response (45%) and on treatment for more than 6 months (55%, with 31% on treatment for more than 1 year). Ordination of microbiome data from all four cancers reveals a small cluster of patients that were NR regardless of cancer type. Although the variance in the composition of pretreatment microbiome samples did not explain response alone (R vs. NR, PERMANOVA, p=0.273), a significant portion of the variance in microbiome composition was explained by the interaction of cancer type and outcome (PERMANOVA, p=0.014), suggesting a cancer-specific microbiome relationship. Notably, there was some similarity in the signature of NR across three of the four cancer types. The relationship observed in this study was also identified and corroborated in pre-clinical models of ICI response. In these models, NR was characterized by active tumor growth in mice and a lack of induction of cytotoxic CD8+ T cells after ICI treatment.

Read this article:
Seres Therapeutics (MCRB) Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at ASCO - StreetInsider.com

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the first patient had been dosed in the Phase 1b/2 investigator-initiated trial, studying the safety and tolerability of plinabulin, in triple combination therapy with both PD-1/PD-L1 antibody (mAb) and radiation therapy (RT). This triple combination is actively recruiting at The University of Texas MD Anderson Cancer Center, with Dr. Vivek Subbiah as principal investigator, in seven metastatic or locally advanced cancers, which include bladder cancer, melanoma, Merkel cell cancer, MSI-H cancers (of any histology), non-small cell lung cancer (NSCLC), renal cell cancer, and small cell lung cancer (SCLC).

The study is titled An Open-label, Single-center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination with Radiation/Immunotherapy in Patients with Select Advanced Malignancies after progression on PD-1 or PD-L1 Targeted Antibodies.

Plinabulin, a selective immunomodulating microtubule-binding agent (SIMBA), induces maturation of dendritic cells (antigen-presenting cells or APCs) resulting in the activation of tumor antigen-specific T-cells to selectively target cancer cells. It has been demonstrated to revert resistance to PD-1/PD-L1 mAb with an objective response rate of 43% when combined with checkpoint inhibitors in a Phase 1 SCLC study, will be presented at 9 a.m. ET on June 4, 2021 at the ASCO Lung Cancer Poster Session (Abstract #8570) (link). This triple combination regimen is supported by data including >80% tumor reduction in PD-1 mAb non-responsive tumor models as presented at AACR in June 2020. Additionally, recent data, published in Frontiers in Oncology1, has shown that plinabulin elicits a strong anti-cancer immune response, which polarizes macrophages and increases the ratio of M1-like/M2-like tumor-associated macrophages, further strengthening the support for the anti-tumor immune effects of plinabulin.

This marks another important step in the continued effort to develop plinabulin franchise as a potential cornerstone agent in combination with checkpoint inhibitors for potential synergistic anti-cancer effect. This is another significant milestone after the recent success of Plinabulin combined with PD-1 and CTLA-4 inhibitors with 43% ORR in patients who failed checkpoint inhibitors with durable treatment effect in Phase 1 SCLC study, said Dr. Ramon Mohanlal, EVP of R&D, CMO of BeyondSpring. We are excited to advance this clinical study in the hopes of providing patients with a combination therapy option that has the potential to have a significant impact on clinical outcomes and to treat patients who failed checkpoint inhibitors in multiple cancers, a severely unmet medical need.

For more information on this trial (NCT04902040), please visit clinicaltrials.gov.

About PlinabulinPlinabulin, BeyondSprings lead asset, is a selective immunomodulating microtubule-binding agent (SIMBA), an NDA-ready asset for CIN prevention indication and a Phase 3 anti-cancer candidate for NSCLC. US FDA granted priority review for Plinabulin and G-CSF combination for CIN prevention with a PDUFA date of November 30, 2021. Plinabulin triggers the release of the immune defense protein, GEF-H1, which leads to two distinct effects: first is a durable anticancer benefit due to the maturation of dendritic cells resulting in the activation of tumor antigen-specific T-cells to target cancer cells and the second is early-onset action in CIN prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs). Plinabulin received breakthrough designation from both US and China FDA for CIN prevention indication. As a pipeline in a drug, plinabulin is being broadly studied in combination with various immuno-oncology agents that could boost the effects of the PD1/PD-L1 antibodies.

About BeyondSpringHeadquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSprings first-in-class lead asset plinabulin is being developed as a pipeline in a drug. It is filed for approval in the US and China for the prevention of chemotherapy-induced neutropenia (CIN) and has a fully enrolled pivotal study to test an anti-cancer benefit with an overall survival primary endpoint in non-small cell lung cancer (NSCLC) Phase 3 study. Additionally, it is being broadly studied in combination with various immuno-oncology regimens that could boost the effects of PD-1/PD-L1 antibodies. In addition to plinabulin, BeyondSprings extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

Investor Contact:Ashley R. RobinsonLifeSci Advisors, LLC+1 617-430-7577arr@lifesciadvisors.com

Media Contact:Darren Opland, Ph.D.LifeSci Communications+1 646-627-8387darren@lifescicomms.com

Original post:
BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of...

NEW YORK, June 3, 2021 /PRNewswire/ --Hoth Therapeutics. (NASDAQ: HOTH), a patient-focusedbiopharmaceutical company,announced today that it will share positive results from a preclinical trial during its shareholder presentation, reinforcing the potential of HT-KIT, a new molecular entity under development for treatment of mast cell-derived cancers and anaphylaxis.

HT-KIT is an mRNA frame-shifting therapeutic designed to specifically target the receptor tyrosine kinase KIT, which is required for the proliferation, survival and differentiation of bone marrow-derived hematopoietic stem cells. Mutations in the KIT pathway have been associated with several human cancers, such as mast cell-derived cancers, systemic mastocytosis with associated hematologic neoplasm, or mast cell leukemia, gastrointestinal stromal tumors, and acute myeloid leukemia.

The preclinical animal trials were conducted using humanized mast cell neoplasm models, representative in vitro and in vivo models for aggressive, mast cell-derived cancers, such as mast cell leukemia and mast cell sarcoma. Key findings of the mouse models found that HT-KIT:

"The results from our HT-KIT preclinical trial further reinforces our belief that targeting mutations in the KIT pathway could be the answer for patients living with mast cell-derived cancers and related conditions," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "Our team looks forward to sharing the data that support our findings in greater detail with our shareholders at the presentation on June 3rd."

The data presentation is open to all shareholders and any parties interested in learning more. Any questions for Hoth Therapeutics and presenters, Dr. Cruse and Dr. Johns can be submitted in advance of the presentation by emailing questions to investorrelations@hoththerapeutics.com.

Meeting Details:Date: Jun 3, 2021Time: 1:00 PM ET

To receive the Zoom meeting details, please click the attached link to register for the event.

https://zoom.us/meeting/register/tJIsc-2uqDktEtJQUD7CrJjzUKJQWSAen7yH

After registering, you will receive a confirmation email containing information about joining the meeting.

Data will also be available for review at the company's 2021 ASCO Annual Meeting exhibit.

About Hoth Therapeutics, Inc.Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19.To learn more, please visithttps://ir.hoththerapeutics.com/.

Forward-Looking StatementThis press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:LR Advisors LLCEmail:investorrelations@hoththerapeutics.comwww.hoththerapeutics.comPhone: (678) 570-6791

Media Relations Contact: MakovskyEmail: hoth-mak@makovsky.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-shares-positive-preclinical-results-of-novel-ht-kit-therapeutic-301305026.html

SOURCE Hoth Therapeutics, Inc.

Read more here:
Hoth Therapeutics Shares Positive Preclinical Results of Novel HT-KIT Therapeutic - BioSpace

Global Cord stem cell banking marketis estimated to reach USD 13.8 billion by 2026 registering a healthy CAGR of 22.4%. The increasing number of parents storing their childs cord blood, acceptance of stem cell therapeutics, high applicability of stem cells are key driver to the market.

Few of the major market competitors currently working in the global cord stem cell banking market are CBR Systems, Inc., Cordlife, Cells4Life Group LLP, Cryo-Cell International, Inc., Cryo-Save AG, Lifecell, StemCyte India Therapeutics Pvt. Ltd, Viacord, SMART CELLS PLUS., Cryoviva India, Global Cord Blood Corporation, National Cord Blood Program, Vita 34, ReeLabs Pvt. Ltd., Regrow Biosciences Pvt. Ltd. , ACROBiosystems., Americord Registry LLC., New York Blood Center, Maze Cord Blood, GoodCell., AABB, Stem Cell Cryobank, New England Cryogenic Center, Inc. among others.

Get Sample Copy Of This Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cord-stem-cell-banking-market&kb

Queries Resolved In This Report:

Market Drivers

Market Restraint

Request for Detailed TOC:https://www.databridgemarketresearch.com/toc/?dbmr=global-cord-stem-cell-banking-market&kb

Key Developments in the Market:

Segmentation: Global Cord Stem Cell Banking Market

By Storage Type

By Product Type

By Service Type

By Indication

By Source

By Geography

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cord-stem-cell-banking-market&kb

How will this Market Intelligence Report Benefit You?

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailingsopan.gedam@databridgemarketresearch.com. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:Corporatesales@databridgemarketresearch.com

See the article here:
Global Cord Stem Cell Banking Market Enormous Growth Insights By 2026||Cryo-Cell International, Inc., Cryo-Save AG, Lifecell, StemCyte India...

RANCHO CORDOVA, Calif., Feb. 17, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc.("ThermoGenesis" or the "Company") (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Company will kick off a year of celebration of its 35th anniversary by aligning its future corporate strategy in offering cell processing systems and services to meet the large-scale cellular manufacturing needs of the increasing number of therapies to be developed over the next decade.

ThermoGenesis has built a solid reputation in the cell banking and cell therapy field. The Company was originally founded in 1986 during a pivotal time, when the stem cell and gene therapy industry was in its infancy. In the early-1990s, ThermoGenesis' original founder, Phil Coelho, formed a long-term collaboration with Dr. Pablo Rubinstein of the New York Blood Center, the father of all cord blood stem cell banking. Together, they invented, patented, and obtained FDA clearance for the first "functionally closed" system for concentrating and isolating stem cells from fresh cord blood samples as well as the protocol for long term cryopreservation of those stem cells to insure retrieval decades later. These breakthrough methods were widely adopted and enabled the cord blood banking industry to grow, expand, and become commercially viable today.

These earliest inventions and protocols were followed by the launch of ThermoGenesis' fully automated BioArchive smart cryopreservation system in 1999 and later its AXP automated cell harvesting system in 2005. These fully automated systems have been adopted by over 130+ leading cord blood transplant centers and other stem cell institutes such as MD Anderson, Cleveland Clinic, Duke University, New York Blood Center in 40+ countries. These systems remain "state-of-the-art" almost 20 years later.

"In the past 20 years, ThermoGenesis and its affiliated companies have helped to advance and shape the landscape of the cell banking industry," said Chris Xu, PhD, Chief Executive Officer of ThermoGenesis. "Cell based therapies have become one of the fastest growing sectors in medicine with over 1,000 clinical trials underway in CAR-T cell therapy alone. As we enter the Company's 35th anniversary, we remain committed to staying as the world's leading technology provider for the cell and gene therapy field."

About ThermoGenesis Holdings, Inc.

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automated processing for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpressplatform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit:www.ThermoGenesis.com.

Company Contact:Wendy Samford916-858-5191[emailprotected]

Investor Contact:Paula Schwartz,Rx Communications917-322-2216[emailprotected]

SOURCE ThermoGenesis Holdings, Inc.

Home

More:
ThermoGenesis Holdings Begins a Year of Celebration of its 35th Anniversary in the Cell Banking and Cell Therapy Industry - PRNewswire

CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic off-the-shelf gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that they have entered into a strategic research and development collaboration to develop TALEN gene-edited iPSC NK and CAR-NK cells.

The financial terms of the partnership include up to $760 million of development, regulatory, and sales milestones from Cytovia to Cellectis for the first 5 TALEN gene-edited iPSC-derived NK products (partnership products). Cellectis will also receive single-digit royalty payments on the net sales of all partnered products commercialized by Cytovia. Cellectis will receive an equity stake of $15 million in Cytovia stock or an upfront cash payment of $15 million if certain conditions are not met by December 31, 2021, as well as an option to invest in future financing rounds.

We are excited to collaborate with Cellectis, a gene-editing pioneer and leader in the development of gene-edited allogeneic cancer therapies, to further accelerate Cytovias NK cell programs, said Dr. Daniel Teper, Chairman & CEO of Cytovia Therapeutics. Cellectis has a deep understanding and proven expertise in gene-edited cell therapies, and their gene editing technology, TALEN, will yield NK and CAR-NK treatments with improved potency, persistence, and safety for a variety of cancers, including solid tumors. We look forward to leveraging Cellectis insights and experience to help move Cytovias CAR-NKs into clinical trials by 2022.

Cellectis will develop custom TALEN, which Cytovia will use to edit iPSCs. Cytovia will be responsible for the differentiation and expansion of the gene-edited iPSC master cell bank into NK cells and will conduct the pre-clinical evaluation, clinical development, and commercialization of the mutually-agreed-upon selected therapeutic candidates. Cellectis is granting Cytovia a worldwide license to its TALEN gene-editing technology, enabling Cytovia to modify NK cells addressing multiple gene targets for therapeutic use in several cancer indications.

We are thrilled to partner with Cytovia, a pioneer in the development of NK cells derived from iPSCs, said Dr. Andr Choulika, CEO of Cellectis. We are looking forward to this collaboration and the opportunity to further expand the potency of our proprietary TALEN gene-editing technology to iPSCs and CAR-NKs. Down the road, this collaboration should allow for NK cell therapies to be made available to cancer patients, which is very much in line with Cellectis mission to provide life-saving product candidates to address unmet patient needs in this field.

About CellectisCellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit http://www.cellectis.com.

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

TALEN is a registered trademark owned by Cellectis.

About Cytovia TherapeuticsCytovia Therapeutics Inc. is a biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company is establishing R&D and GMP manufacturing operations in the greater Boston area and partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem, INSERM, and CytoImmune Therapeutics.Learn more at http://www.cytoviatx.com and follow Cytovia Therapeutics on Social Media (Facebook, LinkedIn, Twitter, and Youtube).

About Gene-Edited, iPSC-derived NK CellsChimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR-NK cell therapy has demonstrated initial clinical relevance without the limitations of CAR-T, such as Cytokine Release Syndrome, neurotoxicity or Graft vs Host Disease (GVHD). In addition, CAR-NKs are naturally allogeneic, available off-the-shelf and may be able to be administered on an outpatient basis. Recent innovative developments with the induced pluripotent stem cell (iPSC)-derived CAR-NKs, an innovative technology, allow large quantities of true off-the-shelf, homogeneous genetically modified CAR NK cells to be produced from a gene-edited iPSC master cell bank, and thus hold promise to expand access to cell therapy for many patients.

For further information, please contact:

Cellectis Media contacts:Margaret Gandolfo, Communications Manager, 646-628-0300, margaret.gandolfo@cellectis.comConor McGoldrick, Zeno Group, Assistant Account Executive, 914-355-0927, Conor.Mcgoldrick@zenogroup.com

Cellectis IR contact:Simon Harnest, SVP, Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com

Cytovia Investor Relations contact: Anna Baran-DjokovicVP of Investor Relations646-355-1787anna@cytoviatx.com

Cytovia Media contact: Chris MaggosLifeSci Advisors+41 79 367 6254chris@lifesciadvisors.com

Disclaimer

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as at this time, believe, expected, forward looking, promising and will, or the negative of these and similar expressions. These forward-looking statements, are based on our managements current expectations and assumptions and on information currently available to management. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2019 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

PDF available at: http://ml.globenewswire.com/Resource/Download/c6bbee7d-f56e-400c-a6a4-28586a9e4851

Visit link:
Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived Natural Killer Cells - BioSpace

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Cell culture supplements are the backbone of culturing methods and techniques in mammalian and microbial cell culture. Routinely performed cell-based assays and cell expansion processes require several growth factors to boost cell growth in the culture. Recombinant cell culture supplements serve an array of applications, such as stem cell research, drug discovery, oncology research, and regenerative medicine. Recombinant cell culture supplements and growth factors are used for culturing stem cells for expansion and differentiation into other cell types. Stem cell research is growing and adoption is increasing with time. Recombinant cell culture supplements such as albumin and transferrin are key components of mammalian cell culture. Increasing bioprocessing activities for production of novel biologics are likely to upswing the growth of the recombinant cell culture supplements market over the coming years.

These days, a majority of supplements used in research and manufacturing are produced using recombinant technology. Recombinant supplements play an important role in gene and cell therapy. Cell therapy requires to grow the cells outside the human body, i.e. in-vitro, and, recombinant cell culture supplements are inevitable for such applications. Due to rapid development within the biopharmaceutical industry, recombinant cell culture supplements are anticipated to witness significant demand through 2031.

According to a latest report published by Persistence Market Research, the global recombinant cell culture supplements market was valued at US$ 441 Mn in 2020, and is predicted to witness an impressive CAGR of over 6% during the forecast period (2021 2031).

Key Takeaways from Recombinant Cell Culture Supplements Market Study

Get the Sample PDF of the Report: https://www.persistencemarketresearch.com/samples/31310

"Increasing drug discovery and preference for recombinant technology for bio- production will upswing the global recombinant cell culture supplements market," says an analyst of Persistence Market Research.

Get Full Access of Report: https://www.persistencemarketresearch.com/checkout/31310

Collaborations & Acquisitions Key Strategies amongst Market Players

Prominent players in the recombinant cell culture supplements market are firming their product ranges through acquisitions and reaching out to emerging markets. Increasing investments and manufacturing capacity expansion are expected to favour the growth the global market over the forecast period

Various players in the recombinant cell culture supplements market are focusing on growth strategies such as acquisitions and collaborations.

What Does the Recombinant cell culture supplements Market Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the recombinant cell culture supplements market in its latest study, presenting historical demand assessment of 2016 2020 and projections for 2021 2031, on the basis of product (recombinant growth factors, recombinant insulin,recombinant albumin, recombinant transferrin,recombinant trypsin, recombinant aprotinin, recombinant lysozyme, and others), application (stem cell therapy, gene therapy,bioprocess application,vaccine development, and others), source (animals, microorganisms, andhumans), and end user (academic and research institutes,biopharmaceutical companies,cancer research centers, and contract research centers (CROs)), across seven key regions of the world.

Browse Research Release at:https://www.persistencemarketresearch.com/market-research/recombinant-cell-culture-supplements-market.asp

Browse End-to-end Market: IndustrialAutomation

Related Reports:

Cell Culture Media Market:

https://www.persistencemarketresearch.com/market-research/cell-culture-media-market.asp

Cell Culture Freezing Market:

https://www.persistencemarketresearch.com/market-research/cell-culture-freezing-market.asp

About Persistence Market Research

Overview:

Persistence Market Research (PMR)is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At Persistence Market Research, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact

Rajendra Singh Persistence Market ResearchU.S. Sales Office:305 Broadway, 7th FloorNew York City, NY 10007+1-646-568-7751United StatesUSA - Canada Toll-Free: 800-961-035Email: [emailprotected]Visit Our Website:https://www.persistencemarketresearch.com

Content Source:https://www.persistencemarketresearch.com/mediarelease/recombinant-cell-culture-supplements-market.asp

SOURCE Persistence Market Research Pvt. Ltd.

See the original post:
Recombinant Growth Factors to Account for Over 45% of Overall Demand through 2031: Persistence Market Research - PRNewswire